Inotek Pharmaceuticals Corporation to Present Phase 2 Data of Trabodenoson in Glaucoma at the Ophthalmology Innovation Summit  
11/2/2012 8:34:08 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL. The data will be presented by Paul G. Howes, President and Chief Executive Officer of Inotek.